Alteration of p16 and p15 genes in human uterine tumours

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 458-467

  Nakashima, R ^a   Fujita, M ^a   Enomoto, T ^a   Haba, T ^b   Yoshino, K ^a   Wada, H ^a   Kurachi, H ^a   Sasaki, M ^b   Wakasa, K ^b   Inoue, M ^c   Buzard, G ^d   Murata, Y ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^d SAIC FREDERICK INC   (United States)

Author keywords

Cervical carcinoma; Endometrial carcinoma; Immunohistochemistry; Methylation; p15; p16

Indexed keywords

DNA; MESSENGER RNA; PROTEIN P15; PROTEIN P16;

ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE DELETION; GENE INACTIVATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC CELL; UTERINE CERVIX CARCINOMA;

ANIMALS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HOMOZYGOTE; HUMANS; MUTATION; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0032928267     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690379     Document Type: Article

References (34)

1. Enomoto T, Weghorst CM, Inoue M, Tanizawa O and Rice JM (1941) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-785
2. Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O and Nomura T (1993) Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53: 1883-1888
3. Foulkes WD, Flanders TY, Pollock PM and Hayward NK (1997) The CDKN2A (p16) gene and human cancer. Mol Med 3: 5-20
4. Fujita M, Inoue M, Tanizawa O, Iwamoto S and Enomoto T (1992) Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 52: 5323-5328
5. Fuqua SAW, Falette NF and McGuire WL (1990) Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst 82: 858-861
6. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen TW, Beart R, Van Tornout JM and Jones PA (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535
7. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952
8. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond) 371: 257-261
9. Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller CW, Strohmeyer T, Wilezynski SP, Melmed S and Koeffler HP (1995) Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 154: 1954-1957
10. Hengstschläger M, Hengstschläger-Ottnad E, Pusch O and Wawra E (1996) The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene 12: 1635-1643
11. INK4B. Cancer Res 56: 722-727
12. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D and Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530
13. Hirama T, Miller CW, Wilezynski SP and Koeffler HP (1996) p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Modern Pathol 9: 26-31
14. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW and Vogelstein B (1994) Detection of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH, (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
16. Kelly MJ, Otterson GA, Kaye FJ, Popescu NC, Johnson BE and Dipaulo JA (1995) CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 63: 226-230
17. Kim JW, Namkoong SE, Ryu SW, Kim HS, Shin JW, Lee JM, Kim DH and Kim IK (1998) Absence of p15(INK4B) and p16(INK4A) gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 70: 75-79
18. Lo K-W, Cheung S-T, Leung S-F, Van Hasselt A, Tsang Y-S, Mak K-F, Chung Y-F, Woo JKS, Lee JCK and Huang DP (1996) Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725
19. Lu X, Toki T, Konishi I, Nikaido T and Fujii S (1998) Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 82: 2409-2417
20. INK4A-mediated growth suppression. Mol Cell Biol 16: 1047-1057
21. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti A and Bevilacqua G (1997). Alterations of p16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol 181: 178-182
22. Merlo A, Herman JG, Mao L, Fee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat MED 1: 686-692
23. Munirajan AK, Kannan K, Bhuvarahamurthy V, Ishida I, Fujinaga K, Tsuchida N and Shanmugam G (1998) The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas uf uterine cervix from India. Gynecol Oncol 69: 205-209
24. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond) 368: 753-756
25. Owen D and Küchn LC (1987) Noncoding 3′ sequences of the transferrin receptor gene are required for mRNA regulation by iron. EMBO J 6: 1287-1293
26. Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR and Birrer MJ (1997) Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol 64: 242-251
27. Peiffer SL, Bartsch H, Whelan AJ, Mutch DG, Herzog TJ and Goodfellow PJ (1995) Low Frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog 13: 210-212
28. Pollock PM, Pearson JV and Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers, non-random distribution of base substitutions. Gene Chromosomes Cancer 15; 77-88
29. Serrano M, Haanon GJ and Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 366: 704-707
30. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW and Stone EM (1993) The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16: 325-332
31. INK4 in human endometrioid-type endometrial carcinoma. Cancer 80: 2250-2256
32. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A (1995) Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55: 2988-2994
33. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T and Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55: 514-517
34. INK4B alterations in primary gynecologic malignancy. Gynecol Oncol 65: 319-324